DrugPatentWatch Database Preview
Drugs in Development Information for Favipiravir
» See Plans and Pricing
What is the drug development status for Favipiravir?
Favipiravir is an investigational drug.
There have been 53 clinical trials for Favipiravir.
The most recent clinical trial was a Phase 3 trial, which was initiated on April 20th 2020.
The most common disease conditions in clinical trials are Coronavirus Infections, Infection, and Severe Acute Respiratory Syndrome. The leading clinical trial sponsors are Novagenix Bioanalytical Drug R&D Center, MDVI, LLC, and Farmagen Ar-Ge Biyot. Ltd. Sti.
There are fifteen US patents protecting this investigational drug and three hundred and three international patents.
Summary for Favipiravir
US Patents | 15 |
International Patents | 303 |
US Patent Applications | 35 |
WIPO Patent Applications | 280 |
Japanese Patent Applications | 0 |
Clinical Trial Progress | Phase 3 (2020-04-20) |
Vendors | 85 |
Recent Clinical Trials for Favipiravir
Title | Sponsor | Phase |
---|---|---|
Investigation the Effect of Montelukast in COVID-19 | Medipol University | Phase 2 |
Investigation the Effect of Montelukast in COVID-19 | The Scientific and Technological Research Council of Turkey | Phase 2 |
Investigation the Effect of Montelukast in COVID-19 | Bahçeşehir University | Phase 2 |
Clinical Trial Summary for Favipiravir
Top disease conditions for Favipiravir
Top clinical trial sponsors for Favipiravir
US Patents for Favipiravir
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
Favipiravir | Start Trial | Nitrogen-containing heterocyclic carboxamide derivatives or salts thereof and antiviral agents comprising the same | Toyama Chemical Co., Ltd. (Tokyo, JP) | Start Trial |
Favipiravir | Start Trial | Pyrazine derivatives or salts thereof, pharmaceutical composition containing the same, and production intermediates thereof | Toyama Chemical Co., Ltd. (Tokyo, JP) | Start Trial |
Favipiravir | Start Trial | Compositions and kits for treating influenza | Adamas Pharmaceuticals, Inc. (Emeryville, CA) | Start Trial |
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Favipiravir
Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
---|---|---|---|---|
Favipiravir | Austria | AT376418 | 2018-08-20 | Start Trial |
Favipiravir | Australia | AU5300499 | 2018-08-20 | Start Trial |
Favipiravir | Australia | AU756635 | 2018-08-20 | Start Trial |
>Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |